What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?

Jane A Cannon, Andrew R McKean, Pardeep S Jhund, John J V McMurray, Jane A Cannon, Andrew R McKean, Pardeep S Jhund, John J V McMurray

Abstract

Each year in the USA there are over 1 million hospital admissions directly related to heart failure (HF). With similar rates across Europe, this places a huge economic burden on healthcare systems globally. Hospitalisation for HF is associated with poor clinical outcomes with 25% of patients being readmitted with signs and symptoms of HF within 1 month of discharge and 10-20% dying in the 6 months after discharge. Although hospital admission could be a sign of disease progression, it is also possible that some of the treatments given acutely for example, inotropic therapy, may result in neurohormonal, haemodynamic and other effects accelerating end-organ damage and contributing to these poor outcomes after discharge. In contrast to the treatment of chronic heart failure (CHF), clinical trials conducted over the past decade in patients with acute HF (AHF) have failed to show significant reductions in morbidity or mortality despite some agents causing beneficial changes in symptoms. As such, the current treatment of patients hospitalised with HF is mainly based on consensus rather than clinical evidence and has changed little over time. We review RELAX-AHF in the context of the other key, large-scale AHF trials conducted over the past 15 years and compare and contrast study design and outcomes in an attempt to determine which factors might be associated with a successful trial in the future.

Keywords: PHARMACOLOGY.

References

    1. Felker GM, Lee KL, Bull DA et al. . Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797–805. 10.1056/NEJMoa1005419
    1. O'Connor CM, Starling RC, Hernandez AF et al. . Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32–43. 10.1056/NEJMoa1100171
    1. Packer M, Colucci W, Fisher L et al. . Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013;1:103–11. 10.1016/j.jchf.2012.12.004
    1. Teerlink JR, Cotter G, Davison BA et al. . Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29–39. 10.1016/S0140-6736(12)61855-8
    1. Bart BA, Goldsmith SR, Lee KL et al. . Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012;367:2296–304. 10.1056/NEJMoa1210357
    1. Chen HH, Anstrom KJ, Givertz MM et al. . Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013;310:2533–43. 10.1001/jama.2013.282190
    1. Cleland JG, Chiswell K, Teerlink JR et al. . Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. Circ Heart Fail 2014;7:76–87. 10.1161/CIRCHEARTFAILURE.113.000284
    1. Cuffe MS, Califf RM, Adams KF et al. . Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. Am Heart J 2000;139(1 Pt 1):15–22. 10.1016/S0002-8703(00)90303-X
    1. Gottlieb SS, Stebbins A, Voors AA et al. . Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). J Am Coll Cardiol 2013;62:1177–83. 10.1016/j.jacc.2013.04.073
    1. Konstam MA, Gheorghiade M, Burnett JC Jr et al. . Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319–31. 10.1001/jama.297.12.1319
    1. McMurray JJ, Teerlink JR, Cotter G et al. . Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009–19. 10.1001/jama.298.17.2009
    1. Mebazaa A, Nieminen MS, Packer M et al. . Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883–91. 10.1001/jama.297.17.1883
    1. Ponikowski P, Mitrovic V, Ruda M et al. . A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J 2014;35:431–41. 10.1093/eurheartj/eht459
    1. Teerlink JR, Metra M, Felker GM et al. . Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;373:1429–39. 10.1016/S0140-6736(09)60622-X
    1. Filippatos G, Teerlink JR, Farmakis D et al. . Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J 2014;35:1041–50. 10.1093/eurheartj/eht497
    1. Ponikowski P, Metra M, Teerlink JR et al. . Design of the RELAXin in acute heart failure study. Am Heart J 2012;163:149–55. 10.1016/j.ahj.2011.10.009
    1. Metra M, Cotter G, Davison BA et al. . Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61:196–206. 10.1016/j.jacc.2012.11.005
    1. Milo-Cotter O, Cotter-Davison B, Lombardi C et al. . Neurohormonal activation in acute heart failure: results from VERITAS. Cardiology 2011;119:96–105. 10.1159/000330409
    1. Pitt B, Pfeffer MA, Assmann SF et al. . Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–92. 10.1056/NEJMoa1313731
    1. Metra M, Ponikowski P, Cotter G et al. . Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Eur Heart J 2013;34:3128–36. 10.1093/eurheartj/eht371
    1. Cotter G, Metra M, Davison BA et al. . Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. Eur J Heart Fail 2014;16:1362–71. 10.1002/ejhf.186
    1. Weatherley BD, Milo-Cotter O, Felker GM et al. . Early worsening heart failure in patients admitted with acute heart failure–a new outcome measure associated with long-term prognosis? Fundam Clin Pharmacol 2009;23:633–9. 10.1111/j.1472-8206.2009.00697.x
    1. Allen LA, Metra M, Milo-Cotter O et al. . Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). J Card Fail 2008;14:777–84. 10.1016/j.cardfail.2008.07.188
    1. Campbell RT, McKean AR, McMurray JJ. Acute heart failure: have we got it all wrong? Eur J Heart Fail 2014;16:1263–7. 10.1002/ejhf.197
    1. Shoaib A, Waleed M, Khan S et al. . Breathlessness at rest is not the dominant presentation of patients admitted with heart failure. Eur J Heart Fail 2014;16:1283–91. 10.1002/ejhf.153
    1. US Department of Health and Human Services. Food and drug administration. Centre for drug evaluation and research. Transcript of 86th Meeting of the Cardiovascular and Renal Drugs Advisory Committee; 1998.
    1. Mebazaa A, Pang PS, Tavares M et al. . The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J 2010;31:832–41. 10.1093/eurheartj/ehp458
    1. Hjalmarson A, Goldstein S, Fagerberg B et al. . Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295–302. 10.1001/jama.283.10.1295
    1. Clinical . Efficacy, Safety and Tolerability of Serelaxin when added to standard therapy in AHF (RELAX-AHF-2). NCT01870778 2015.
    1. Clinical Trials.Go. Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure (TRUE-AHF) 2014.
    1. Clinical . Study to Evaulate the Safety and Efficacy of IV Infusion Treatment with Omecamtiv Mecarbil in Subjects with Left Ventricular Systolic Dysfunction Hospitalised for Acute Heart Failure (ATOMIC-AHF) 2014.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever